Adverse effects of the Medicare PSI-90 hospital penalty system on revenue-neutral hospital-acquired conditions WV Padula, JM Black, PM Davidson, SY Kang, PJ Pronovost Journal of Patient Safety 16 (2), e97-e102, 2020 | 51 | 2020 |
Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries SY Kang, MJ DiStefano, MP Socal, GF Anderson Health Affairs 38 (5), 804-811, 2019 | 38 | 2019 |
Financial eligibility criteria and medication coverage for independent charity patient assistance programs SY Kang, A Sen, G Bai, GF Anderson Jama 322 (5), 422-429, 2019 | 37 | 2019 |
Comparative Approaches to Drug Pricing SY Kang, G Bai, MJ DiStefano, MP Socal, F Yehia, GF Anderson Annual Review of Public Health 41, 499-512, 2020 | 29 | 2020 |
Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context SY Kang, G Bai, L Karas, GF Anderson American journal of public health 109 (4), 559-561, 2019 | 16 | 2019 |
Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs MJ DiStefano, SY Kang, F Yehia, C Morales, GF Anderson Value in Health, 2021 | 15 | 2021 |
Characteristics of Copayment Offsets for Prescription Drugs in the United States AP Sen, SY Kang, E Rashidi, D Ganguli, G Anderson, GC Alexander JAMA Internal Medicine, 2021 | 14 | 2021 |
Critical care beds with continuous lateral rotation therapy to prevent ventilator-associated pneumonia and hospital-acquired pressure injury: a cost-effectiveness analysis SY Kang, MJ DiStefano, F Yehia, MV Koszalka, WV Padula Journal of Patient Safety 17 (2), 149-155, 2021 | 10 | 2021 |
Pharmaceutical Industry Funding to Patient-Advocacy Organization: A Cross-National Comparison of Disclosure Codes and Regulation L Karas, R Feldman, G Bai, SY Kang, GF Anderson Hastings Int'l & Comp. L. Rev. 42, 453, 2019 | 8 | 2019 |
Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply SY Kang, D Polsky, JB Segal, GF Anderson Health Affairs 40 (6), 1000-1005, 2021 | 7 | 2021 |
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance MJ DiStefano, SY Kang, S Parasrampuria, GF Anderson JAMA Health Forum 4 (5), e231090-e231090, 2023 | 6 | 2023 |
Factors Associated With Manufacturer Drug Coupon Use at US Pharmacies SY Kang, AP Sen, JF Levy, J Long, GC Alexander, GF Anderson JAMA Health Forum 2 (8), e212123-e212123, 2021 | 6 | 2021 |
Patterns of Manufacturer Coupon Use for Prescription Drugs in the US, 2017-2019 SY Kang, A Liu, G Anderson, GC Alexander JAMA Network Open 6 (5), e2313578-e2313578, 2023 | 2 | 2023 |
Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs SY Kang, MP Socal, G Bai, GF Anderson Journal of General Internal Medicine 36 (2), 555-556, 2021 | 2 | 2021 |
Guarding Against Seven Common Threats to the Credible Estimation of COVID-19 Policy Effects EF Drabo, SY Kang, CL Gong American Journal of Public Health 110, 1724-1725, 2020 | 2 | 2020 |
Hospital and Physician Group Practice Participation in Prior and Next-Generation Value-Based Payment Programs SY Kang, G Anderson JAMA Network Open 7 (2), e240392-e240392, 2024 | 1 | 2024 |
Innovation in the United States Health-Care System’s Organization and Delivery MJ DiStefano, SY Kang, MP Socal, GF Anderson The School of Public Policy Publications, 2022 | 1 | 2022 |
Association of Hospitals' Experience with Bundled Payment for Care Improvement Model with the Diffusion of Acute Hospital Care at Home SY Kang Health Services Research, 2024 | | 2024 |
Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The “GoodRx” Model J Curran, Y Wang, SY Kang, A Xuan, G Anderson, G Bai, GC Alexander Value in Health 27 (1), 35-42, 2024 | | 2024 |
How Does out-of-Pocket Spending on Ultra-Expensive Drugs Compare between Medicare Part D Beneficiaries and the Commercially Insured Population? M DiStefano, SY Kang, S Parasrampuria, G Anderson 2023 Annual Research Meeting, 2023 | | 2023 |